AQEMIA, a tech-enabled drug discovery company that uses generative AI and deep physics to find new drugs, has secured an additional €30 million investment, bringing its Series A round to €60 million. The round was led by Wendel Growth and supported by existing investors Bpifrance Large Venture, Eurazeo and Elaia.
The funding comes after AQEMIA’s successful drug discovery collaborations with Sanofi and other partners, as well as the progress of its own pipeline of drug candidates, mainly in oncology and immuno-oncology. AQEMIA plans to use the new capital to expand its team, scale its GenAI and deep physics platform, and accelerate its internal drug discovery programs across various therapeutic areas.
“AQEMIA’s journey continues: We’re advancing to clinical trials. We are committed to leading the change in a new era of drug discovery innovation, by embracing generative AI and rigorous physics as key instruments to bring excellence in small molecule drug discovery.” said Maximilien Levesque, CEO and co-founder of AQEMIA.
“We are delighted to be supporting this team, led by Maximilien Levesque and Emmanuelle Martiano, in its mission to find tomorrow’s medicines faster and more effectively. The technology developed by AQEMIA from fundamental research and applied to medical research is unique in the world.” said Victoire Laurenty, Investment Director for Wendel Growth.
AI drug discovery startup Noetik secures $14 million in seed funding